Durect clinical trials

Acquired by Bausch Health Companies Inc., Sep 2025 · source ↗

The registry lists 15 studies whose lead sponsor is Durect. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 24, 2024.

Studies

Recruiting first, then most recently updated. Showing 15 of 15. All Bausch Health Companies Inc. studies →

• A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic HepatitisCompletedNCT03432260Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentCompletedNCT04563026Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)TerminatedNCT03394781Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque PsoriasisCompletedNCT03837743Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney InjuryTerminatedNCT04447404Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• An Extension Trial to Evaluate Long-term Safety of SABER™-Bupivacaine for Pain Following Shoulder SurgeryCompletedNCT01139866

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back PainCompletedNCT01096966Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• Trial of Extended Release Bupivacaine for Pain Relief After SurgeryCompletedNCT02574520Phase 3

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder SurgeryCompletedNCT00993798Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing HysterectomyCompletedNCT00993226Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• A Safety and Effectiveness Study of SABER®-Bupivacaine for Pain Following Shoulder SurgeryCompletedNCT00818363Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• Bupivacaine Effectiveness and Safety in SABER® TrialCompletedNCT01052012Phase 3

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• A Safety and Efficacy Study of SABER®-Bupivacaine for Pain Following Hernia RepairCompletedNCT00974350Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic PainCompletedNCT00485225Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.

• Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic NeuralgiaCompletedNCT00478179Phase 2

  Sponsor listed in the registry: Durect · First submitted before Durect became part of Bausch Health Companies Inc.